SCHEMBL4674402

SCHEMBL4674402

O=C(Cc1ccc(Cc2ccccc2F)o1)C(=O)c1nn[nH]n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.35
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
HTT P42858 1/20 0.33
AR P10275 1/20 0.33
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
CXCR3 P49682 3/20 0.32
MMEL1 Q495T6 1/20 0.32
ACHE P22303 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
MPO P05164 1/20 0.31
MAPK1 P28482 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671114 0.83 CES1 (0.44) CES1NCEH1HTTERCC5FEN1
SCHEMBL4673700 0.83 PTGDR2 (0.35) PTGDR2CES1NCEH1ARALDH1A1
SCHEMBL4670705 0.83 PTPN1 (0.35) PTGDR2CES1NCEH1ARALDH1A1
SCHEMBL4677055 0.82 AR (0.33) HTTARALDH1A1NPC1RAB9A
SCHEMBL4670733 0.82 AR (0.36) PTGDR2CES1NCEH1HTTAR
SCHEMBL4675641 0.82 NPC1 (0.35) PTGDR2CES1NCEH1ARALDH1A1
SCHEMBL3228436 0.81 CXCR3 (0.34) PTGDR2CES1NCEH1L3MBTL1CXCR3
SCHEMBL4677164 0.81 PTGDR2 (0.38) PTGDR2CES1NCEH1HTTAR
SCHEMBL4671973 0.81 ERCC5 (0.36) PTGDR2CES1NCEH1HTTAR
SCHEMBL4677550 0.80 MPO (0.34) PTGDR2CES1NCEH1HTTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGDR2 4591/4885CES1 445/4885NCEH1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.